KRAS and colorectal carcinoma: In colorectal cancer (CRC), KRAS mutant tumor cells increased glycolysis and glutamine utilization resulting in cell death upon inhibition of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [54, 55].